Acadia Pharmaceuticals (ACAD) PT LIfted to $44 at Piper Jaffray Amid Panel Backing for NUPLAZID
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil settles up 2% after Trump rejects return to Iran ceasefire deal terms
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Ovintiv adds 41,000 acres in Permian and Montney deals
- Rubrik (RBRK) Tops Q2 EPS by 16c, Beats on Revenue; Offers FY27 EPS Guidance
Acadia Pharma (ACAD) Fades Early Gains
March 30, 2016 11:56 AM EDTAcadia Pharma (NASDAQ: ACAD) is fading early gains after an FDA panel backed the company's Nuplazid.
Worries about a potential Black Box Warning could be to blame.
Shares are up 9.8% after opening up 20%.
... MoreAegis Capital Affirms Acadia Pharma (ACAD) at 'Buy' Following Positive FDA Panel Review; Sees Nuplazid Approval Soon
March 30, 2016 10:44 AM EDTAegis Capital affirms Acadia Pharma (Nasdaq: ACAD) with a Buy rating and $54 price target following a positive FDA panel review of Acadia's Nuplazid on Tuesday.
Analyst Robert LeBoyer sees post-approval studies for Nuplazid, commenting, Following the results of the Phase III trial in 2013, Acadia met with the FDA and was encouraged to file based only on that trial. Its strong results... More
Needham & Company Remains Bullish on Acadia Pharma (ACAD) Following Positive FDA Vote on Nuplazid
March 30, 2016 6:49 AM EDTNeedham & Company reiterated a Buy rating and $49.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD) following a vote by the FDA Psychopharmacologic Drugs Advisory Committee in favor of Nuplazid approval for treatment of Parkinson's Disease Psychosis. Committee members generally viewed Nuplazid as effective, with a few... More
Acadia Pharma (ACAD) Announces Favorable FDA Panel Vote on NUPLAZID for the Treatment of Psychosis Associated with Parkinson's Disease
March 29, 2016 5:14 PM EDTACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced that the U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) voted 12 to 2 that the benefits of NUPLAZID (pimavanserin) for the treatment of psychosis associated with Parkinsons disease outweigh the risks of... More
Acadia Pharma (ACAD) wins FDA panel backing for Nuplazid - Bloomberg
March 29, 2016 3:37 PM EDTAcadia Pharma (NASDAQ: ACAD) wins FDA panel backing for Nuplazid, according to Bloomberg.
... More